An open lable randomized controlled trial for folic acid and vitamin B12 versus vitamin C in the intervention of the patients with mild cognitive impairment

注册号:

Registration number:

ChiCTR-ROC-16008305 

最近更新日期:

Date of Last Refreshed on:

2018-02-14 21:44:24 

注册时间:

Date of Registration:

2016-04-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

叶酸、维生素B12联合及维生素C对轻度认知功能障碍老年人干预效果的研究

Public title:

An open lable randomized controlled trial for folic acid and vitamin B12 versus vitamin C in the intervention of the patients with mild cognitive impairment

注册题目简写:

English Acronym:

研究课题的正式科学名称:

叶酸、维生素B12联合及维生素C对轻度认知功能障碍老年人干预效果的研究

Scientific title:

An open lable randomized controlled trial for folic acid and vitamin B12 versus vitamin C in the intervention of the patients with mild cognitive impairment

研究课题代号(代码):

Study subject ID:

天津市科技支撑计划项目(项目编号:15ZCZDSY01040)

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

马菲 

研究负责人:

黄国伟 

Applicant:

Fei Ma 

Study leader:

Guowei Huang 

申请注册联系人电话:

Applicant telephone:

+86 13821563872

研究负责人电话:

Study leader's telephone:

+86 22-83336606

申请注册联系人传真 :

Applicant Fax:

+86 22-83336603

研究负责人传真:

Study leader's fax:

+86 22-83336603

申请注册联系人电子邮件:

Applicant E-mail:

mafei@tmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

huangguowei@tmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

www.tmu.edu.cn

申请注册联系人通讯地址:

天津市和平区气象台路22号天津医科大学公共卫生学院

研究负责人通讯地址:

天津市和平区气象台路22号天津医科大学公共卫生学院

Applicant address:

School of Public Health, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin, China

Study leader's address:

22 Qixiangtai Road, Heping District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

300070

研究负责人邮政编码:

Study leader's postcode:

300070

申请人所在单位:

天津医科大学

Applicant's institution:

Tianjin Medical University

研究负责人所在单位:

天津医科大学

Affiliation of the Leader:

Tianjin Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TMUhMEC2016002

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津医科大学医学伦理委员会

Name of the ethic committee:

The Ethics Committee of Tianjin Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2016-04-05 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津医科大学

Primary sponsor:

Tianjin Medical University

研究实施负责(组长)单位地址:

天津市和平区气象台路22号天津医科大学公共卫生学院

Primary sponsor's address:

22 Qixiangtai Road, Heping District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学

具体地址:

天津市和平区气象台路22号

Institution
hospital:

Tianjin Medical University

Address:

22 Qixiangtai Road, Heping District, Tianjin, China

经费或物资来源:

天津市科技支撑计划项目(项目编号:15ZCZDSY01040)

Source(s) of funding:

Tianjin science and technology supporting plan project (No. 15ZCZDSY01040)

Target disease:

Mild Cognitive Impairment (MCI)

Target disease code:

ICD10:F06.751

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

通过检测MCI患者及对照组人群血液叶酸、B12水平、蛋氨酸循环产物、AD相关基因表达等,探讨叶酸、B12对改善MCI患者认知功能的作用及其作用机制。  

Objectives of Study:

The serum folate, serum vitamin B12, plasma homocysteine, S-adenosylmethionine, S-adenosylhomocysteine, methionine cycle products, and AD related gene in blood are detected, to explore the effects of folic acid and vitamin B12 on the cognitive function of the patients with MCI.

药物成份或治疗方案详述:

叶酸;维生素B12 

Description for medicine or protocol of treatment in detail:

folic acid, vitamin B12 

纳入标准:

①年龄65岁以上社区老年人群;
②记忆减退主诉大于6个月;
③采用MMSE中文版测量认知能力得分低于按年龄、文化程度区组标准界值分;
④生活及社会功能有降低: 日常生活能力量表得分≤18分;
⑤不符合痴呆诊断标准,精神疾病,脑损伤和其他神经精神状态导致的失能。
同时符合上述5条者被认定为发生MCI,纳入本次研究。

Inclusion criteria

1. Community-based elderly subjects aged more than 65 years old;
2. Memory complaints reported by the patient, family, or physician, of at least a 6-month duration and preferably corroborated by an informant;
3. Mild quantitative impairments in cognitive function were assessed by the Chinese version of the 30-point Mini Mental State Examination (MMSE) using age- and education-based norms (cutoff point was set at 1.5 SD below the mean age- and education-adjusted MMSE scores);
4. Decreased daily living ability and social function, as measured by the daily living scale, score is below 18.
5. Absence of dementia (according to DSM-IV criteria), psychiatric disorder, cerebral damage, or any active neuropsychiatric condition producing disability;
Subjects conforming to five items above can be determined as MCI and included in our study.

排除标准:

①神经系统检查明显偏瘫、偏身感觉障碍、失语等局灶性中枢神经障碍体征,脑血管病史(包括出血性和缺血性),发生内脑外伤或骨折;
②喘息性支气管炎、严重高血压、心绞痛及严重感染等内科疾病;
③明显抑郁、焦虑情绪等精神病患者及其它内分泌系统疾病史(如甲亢、甲状腺功能低下、系统性红斑狼疮、类风湿关节炎等);
④新发现、进展期或晚期肿瘤;
⑤胃肠手术或患严重胃肠疾病者;
⑥明显影响认知功能测试的视觉、听觉障碍或语言交流困难;
⑦酒精依赖及其他精神活性物质滥用病史(如抗精神病药、苯二氮卓类药等),或服用影响认知功能药物
⑧身上有金属装备,如起搏器者。

Exclusion criteria:

1. Neurological examination found the sign of local central nerve obstruction such as obvious paralysisunilateral sensory disturbance and aphasia etc, history of cerebrovascular diseases (hemorrhagic and ischemic stroke), brain injury or bone fracture;
2. Medical diseases such as asthmatic bronchitissevere hypertensionangina pectoris and severe infection;
3. Psychotic patients with evident anxiety and depressed emotion and subjects with endocrine system history of disease(hyperthyroidism,thyroid hypofunction, systemic lupus eythematosus, rheumatoid arthritis);
4. Newly discovered or advanced tumor;
5. Surgery or diseases of the stomach or small intestine;
6. Visual perception,auditory perceptual disorders or languages communication difficulties,all of which may influence measurement of cognitive function;
7. Alcohol dependence and other psychoactive substance abuse such as antipsychotic drug,benzodiazepines or taking medicine influencing cognitive function;
8. Who have implanted metallic devices such as pacemakers.

研究实施时间:

Study execute time:

From 2016-03-01 00:00:00 To 2017-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2016-05-30 00:00:00 To 2016-07-30 00:00:00  

干预措施:

Interventions:

组别:

MCI联合干预组

样本量:

60

Group:

MCI combined intervention group

Sample size:

干预措施:

督促服用叶酸0.8mg/天,维生素B12 25μg/天,口服,18个月

干预措施代码:

Intervention:

Folic acid, 0.8mg /day, Vitamin B12 25μg /day, oral, eighteen months

Intervention code:

组别:

MCI叶酸干预组

样本量:

60

Group:

MCI folic acid intervention group

Sample size:

干预措施:

督促服用叶酸0.8mg/天,口服,18个月

干预措施代码:

Intervention:

folic acid, 0.8mg /day, oral, eighteen months

Intervention code:

组别:

MCI维生素B12干预组

样本量:

60

Group:

MCI vitamin B12 intervention group

Sample size:

干预措施:

督促服用维生素B12 25μg/天,口服,18个月

干预措施代码:

Intervention:

vitamin B12 25μg/day, oral, eighteen months

Intervention code:

组别:

维生素C对照组

样本量:

60

Group:

vitamin C control group

Sample size:

干预措施:

维生素C(100mg/片,1片/日)

干预措施代码:

Intervention:

Vitamin C 100mg/day

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China 

Province:

Tianjin 

City:

 

单位(医院):

天津市滨海新区塘沽三槐路社区卫生服务中心 

单位级别:

二甲医院 

Institution
hospital:

Sanhuailu communityhealth service center in the new coastal region of Tianjin

Level of the institution:

Secondary A hospital

测量指标:

Outcomes:

指标中文名:

血清叶酸

指标类型:

主要指标

Outcome:

serum folate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清维生素B12

指标类型:

主要指标

Outcome:

serum vitaminB12

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

韦氏成人智力量表(中文版)

指标类型:

主要指标

Outcome:

Wdchsler Intelligence Scale(Chinese version)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子

指标类型:

次要指标

Outcome:

tumor necrosis factor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素-6

指标类型:

次要指标

Outcome:

Interleukin 6 (IL-6)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血浆Aβ40

指标类型:

次要指标

Outcome:

plasma Aβ40

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

S-腺苷甲硫氨酸

指标类型:

次要指标

Outcome:

S-adenosylmethionine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血浆同型半胱氨酸

指标类型:

次要指标

Outcome:

plasma homocysteine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

S-腺苷同型半胱氨酸

指标类型:

次要指标

Outcome:

S-adenosylhomocysteine

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

对本研究不知情统计分析人员,采用随机数字法

Randomization Procedure (please state who generates the random number sequence and by what method):

statistics analyst ignorant to this study uses random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲法

Blinding:

Using double blind method

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

not in public

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

SPSS18.0

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Statistical Package for the Social Sciences (SPSS) version 18.0 (SPSS Inc.)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2016-04-19 00:06:20